Explore 3 Stock Ideas & Industry Insights Download Free Report

News

BofA Downgrades ProKidney Corp. (NASDAQ: PROK) to Underperform

BofA Securities issued a notable downgrade forProKidney Corp. (NASDAQ: PROK)on Monday, shifting its rating fromNeutraltoUnderperformand sharply reducing its price target from USD3.00 to USD1.00 per share. The reassessment follows a combination of revised expectations for ProKidney’s lone therapeutic candidate, REACT, and growing caution regarding …

Team Kalkine | 30 June 2025

Stocks Rally on Trade Optimism, Rate Cut Hopes, and Easing Geopolitical Tensions

Market Movers:On Friday, the top gainers were Locafy Limited (+225.49%), followed by Blue Gold Limited (+210.79%). On the contrary CID HoldCo, Inc (-47.23%) Liminatus Pharma, Inc (- 42.89%) declined the most the same day.

Team Kalkine | 30 June 2025

Goldman Sachs Upgrades Affiliated Managers Group (NYSE: AMG) to Buy, Sets USD 218 Price Target

Goldman Sachs on Thursday upgraded shares of Affiliated Managers Group, Inc. (NYSE: AMG) fromNeutraltoBuy, assigning a price target of USD218.00. The new target suggests an approximate 17% upside from AMG’s current trading levels near USD199.52, which sits close to the stock’s 52-week high.

Team Kalkine | 30 June 2025

Wall Street Zen Upgrades British American Tobacco (NYSE:BTI) to Buy Amid Mixed Analyst Sentiment

Shares of British American Tobacco plc (NYSE:BTI)received an upgrade from Wall Street Zen over the weekend, with the firm lifting its rating from “Hold” to “Buy,” according to a research note issued on Saturday. This adjustment follows a series of recent analyst updates that …

Team Kalkine | 30 June 2025

Autolus Therapeutics (NASDAQ:AUTL) Reports 55.4% Estimated 3-Year Overall Survival in FELIX Trial of Obe-cel

Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company focused on programmed T cell therapies, has announced updated results from its ongoing FELIX trial evaluating obe-cel, an autologous CD19 CAR T-cell therapy, in adults with relapsed or refractory (r/r) CD19-positive B-cell acute lymphoblastic leukemia (B-ALL).

Team Kalkine | 30 June 2025

Lemonade (NYSE: LMND) Achieves USD 1B IFP, Grows Revenue by 27% in Q1

Lemonade Inc. (NYSE: LMND)is a U.S.- and Europe-based insurer offering renters, homeowners, auto, pet, and life insurance through multiple sales channels.

Team Kalkine | 28 June 2025

Global Markets Rally on Trade Deals, Fed Rate Cut Hopes, and Geopolitical Easing

Index Update:S&P 500 and Nasdaq 100 futures pointed to record-high openings, with the Dow set to rise by 150 points, driven by optimism over a new U.S.–China trade agreement that eases tariffs and secures rare earth supplies. Additional progress with India and the removal …

Team Kalkine | 27 June 2025

Sanford C. Bernstein Initiates Coverage on ASML (NASDAQ: ASML) with “Market Perform” Rating, Sets USD 806 Target

ASML Holding N.V. (NASDAQ: ASML), a key supplier of lithography equipment for the semiconductor industry, has been the focus of multiple research reports, reflecting a spectrum of views on the company’s valuation and growth outlook. In the latest update, Sanford C. Bernstein initiated coverage …

Team Kalkine | 27 June 2025